Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research progress on pathogenesis, diagnosis and treatment of liver cancer

( views:208, downloads:53 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 18

DOI:: 10.3969/j.issn.1009-3079.2006.18.001

Key Word:: 肝癌;致癌基因;抑癌基因;中西医结合治疗;综合诊疗;分子治疗

Abstract：作为癌症第三号杀手,肝癌的发生、发展是经历多阶段和多因素作用,通过癌基因启动、促癌和演进等步骤.目前已知不少基因与肝癌相关,并开展了前沿性的分子治疗研究,有些在动物和临床实验中已取得了初步成效.另一方面,传统中西医诊疗也随着科技发达而有长足进展,近年更积极推行综合治疗手段.在分子诊疗的年代,本文除了对各诊疗方法及其综合应用方案有较详尽的阐述外,还就最新的分子诊疗进行了探讨,期望不久将来,人类能更有效地防治这威胁着生命的恶性肿瘤.

Reference

[1]王克敏,夏爱娣,陈诗书.脂质体介导mIL-12基因与MHCⅠ基因联合对小鼠实验性肝癌的治疗作用[J].2002,(10).
[2]LIN Zhou,Jia Liu,Feng LUO.Serum tumor markers for detection of hepatocellular carcinoma[J].2006,(8).
[3]吴荻,鲍万国,丁艳华,等.消水汤治疗原发性肝癌腹水的临床及实验研究[J].2005,(12).
[4]Guang-Neng Zhu,LI Zuo,Qing Zhou,etc.Loss of heterozygosity on chromosome 10q22-10q23 and 22q 11.2-22q12.1 and p53 gene in primary hepatocellular carcinoma[J].2004,(13).
[5]Yong-Song Guan,Yuan LIU,Long Sun,etc.Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization[J].2005,(24).
[6]Ji-Hui Hao,MING Yu,Hui-Kai Li,etc.Inhibitory effect of antisense vascular endothelial growth factor RNA on the profile of hepatocellular carcinoma cell line in vitro and in vivo[J].2006,(7).
[7]Zhi-Zhen Dong,Deng-Fu Yao,Deng-Bing Yao,etc.Expression and alteration of insulin-like growth factor Ⅱ-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma[J].2005,(30).
[8].Gene Therapy of Cancer: Induction of Anti-Tumor Immunity[J].2004,1(2).
[9]曹志成,余坚文,梁荣能.蛋白质组学--引领后基因组时代[J].2005,(1).
[10]Xiao-Yong Fu,Hong-yang WANG,LU Tan,etc.Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance[J].2002,(4).
[11]李雁,汤钊猷,田波,等.细胞角质蛋白19与肝癌临床病理关系的探讨[J].2004,(6).
[12]于尔辛.恢复机体的和谐有序--探索肿瘤病人的辨证论治[J].2003,1(3).
[13]Zhang PH,Zou L,Tu ZG.RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity.[J].2006,131(1).
[14]Wheeler VC,Aitken M,Coutelle C.Modification of the mouse mitochondrial genome by insertion of an exogenous gene.[J].1997,198(1/2).
[15]Muller M,Fleischer B,Schuchmann M,etc.Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma.[J].2006,28(1).
[16]Fran?oise, Degos.[Vaccination against hepatitis B virus].[J].2006,35(2 Pt 2).
[17]Guido M,Pacenti M,Parolin C,etc.Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma.[J].2005,42(5).
[18]Horgan K,Sheehan S,Muzikansky A,etc.Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.[J].2006,24(12).
[19]A T, De Souza,G R, Hankins,M K, Washington,etc.Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors.[J].1995,10.
[20]Hitoshi, Ishikawa,Hiroshi, Tsuji,Hirohiko, Tsujii.[Clinical experience of carbon ion radiotherapy for malignant tumors].[J].2006,33.
[21]Noda Katsuhisa,Nagano Hiroaki,Ito Yasuhiro,etc.Linkage of elevated ets-2 expression to hepatocarcinogenesis.[J].2002,22(4).
[22].The Relationship Between Point Mutation and Abnormal Expression of C-FMS Oncogene in Hepatocellular Carcinoma[J].2004,(1).
[23]Shiu-Feng Huang,Hey-Chi Hsu,Jonathan A Fletcher.Investigation of Chromosomal Aberrations in Hepatocellular Carcinoma by Fluorescence In Situ Hybridization[J].1999,111(1).
[24]Pisani P,Ferlay J,Parkin DM,etc.Global cancer statistics, 2002.[J].2005,55(2).
[25]Gong Z,Lam SH.Modeling liver cancer using zebrafish: a comparative oncogenomics approach.[J].2006,5(6).
[26]Krzywda S,Higashitsuji H,Fujita J,etc.The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.[J].2004,279(2).
[27]Peter Fritz,Hans-Jörg Kraus,Wolfram Dölken,etc.Technical Note: Gold Marker Implants and High-Frequency Jet Ventilation for Stereotactic, Single-Dose Irradiation of Liver Tumors[J].2006,5(1).
[28]Zhang X,Zhang H,Ye L.Effects of hepatitis B virus X protein on the development of liver cancer.[J].2006,147(2).
[29]Li Z,Zhao X,Zhou Y,etc.Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells.[J].2005,79(22).
[30]Thomas MB,Abbruzzese JL.Opportunities for targeted therapies in hepatocellular carcinoma.[J].2005,23(31).
[31]Adriana, Vince.[Hepatitis B and C: natural course of disease].[J].2005,59(5).
[32]X, Zhang,H J, Xu,Y, Murakami,etc.Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma.[J].1994,54.
[33]Ropero AM,Danovaro Holliday MC,Andrus JK.Progress in vaccination against hepatitis B in the Americas.[J].2005,34(Suppl.2).
[34]Ikenoue T,Omata M,Sato S,etc.Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment.[J].2005,5(16).
[35]Sakai M,Nomoto S,Kanazumi N,etc.Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma.[J].2005,52(66).
[36]Zavos C,Chatzopoulos D,Kountouras J.Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies.[J].2005,90(4).
[37]Lavanchy D.Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention.[J].2005,34(Suppl.1).
[38]Drexhage H,Vukosavljevic D,Mancham S,etc.Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma.[J].2006,37(3).
[39]Wu MC,Wang HY,Ullrich A,etc.Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma.[J].2002,21(32).
[40]Deng G,Cassileth BR.Integrative oncology: complementary therapies for pain, anxiety, and mood disturbance.[J].2005,55(2).
[41]Shibata K,Sasaki A,Inomata M,etc.Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma.[J].2005,52(66).
[42]Philip R,Evans AA,Mehta AS,etc.Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma.[J].2006,5(2).
[43]Hui KK,Hui EK,Johnston MF.The potential of a person-centered approach in caring for patients with cancer: a perspective from the UCLA center for East-West medicine.[J].2006,5(1).
[44]ZENG Jin-xiong,LIN Jian-jun,ZHENG Min-lin,etc.Clinical Study on Treatment of Primary Hepatocellular Carcinoma by Shenqi Mixture Combined with Microwave Coagulation[J].2005,11(2).
[45]Wang X,Chua D,Sham J,etc.Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.[J].2006,13(5).
[46]Lim JWE,Ou KL,Chung MCM,etc.Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma[J].2006,580(9).
[47]Chan WC.Bionanotechnology progress and advances.[J].2006,12(1 Suppl.1).
[48]Kock R,Manns M,Kuhnel F,etc.VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo.[J].2002,9(6).